Medibiofarma develops first-in-class small molecules targeting T-Cell infiltration to treat complex diseases such as Crohn's disease and neurodegeneration. The company focuses on drug design and medicinal chemistry, advancing therapies through clinical trials to address unmet medical needs in these areas.
Funding
Funding not disclosed
Founders
Product
Problem
Many complex diseases, such as Crohn's disease and neurodegenerative conditions, are characterized by excessive T-cell infiltration into affected tissues, leading to inflammation and tissue damage. Current treatments often lack specificity and can have significant side effects, highlighting the need for more targeted therapies.
Solution
Medibiofarma is developing first-in-class small molecule drugs designed to modulate T-cell infiltration, offering a targeted approach to treating complex diseases. Their approach centers on innovative, target-based medicinal chemistry to create new chemical entities (NCEs) with clinical proof-of-concept data in human patients. By selectively modulating T-cell activity, Medibiofarma aims to reduce inflammation and tissue damage in diseases like Crohn's and Huntington's disease, potentially leading to improved patient outcomes and reduced side effects compared to existing treatments. The company focuses on drug design, medicinal and synthetic chemistry, in vitro pharmacology, intellectual property, clinical trials, and business development.
Target Audience
The primary target audience includes patients suffering from complex diseases characterized by T-cell infiltration, such as Crohn's disease and neurodegenerative disorders like Huntington's disease, as well as the healthcare providers who treat them.
Features
- First-in-class small molecules designed to modulate T-cell infiltration
- Target-based medicinal chemistry approach for drug discovery
- Clinical-stage programs in Crohn's disease (MBF-118) and Huntington's disease (MBF-015)
- Focus on developing new chemical entities (NCEs) with clinical proof-of-concept data